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C-kit (CD117) encodes the transmembrane receptor tyrosine kinase KIT, whose intracellular kinase activity is stimulated after binding of the ligand stem cell factor (SCF) to the extracellular receptor. KIT is expressed in hematopoietic progenitor cells, mast cells, interstitial cells of Cajal (ICCs), germ cells and melanocytes. Gain-of-function mutations result in an SCFindependent tyrosine kinase activity and cause malignancies of each of these cell types, that is, acute myelogenous leukemia (AML), mastocytosis, gastrointestinal stromal tumors (GISTs), germ cell tumors and melanomas (for a review, see reference Akin and Metcalfe 2 ). Loss-of-function mutations of c-kit, in contrast, were shown to cause piebaldism, an autosomal dominantly inherited disorder characterized by congenital patches of white skin and hair that lack melanocytes (for a review, see reference Spritz 3 ). Notably, the 541 Leu c-kit variation was also very recently described in a family with piebaldism from the Netherlands. Although functional analysis was not performed, the authors suggested that 541
Leu may impair insertion of the KIT receptor into the cell membrane or may affect dimerization of the receptor polypeptide. They concluded that this sequence variation may have a disease-causing, loss-of-function effect. 4 To evaluate the role of the c-kit M541L and N564K sequence variations in Caucasians, we screened 102 CML patients and 166 healthy controls from Germany. The diagnosis of CML was based on clinical criteria and hematological data. The diagnosis was confirmed by demonstration of the bcr-abl fusion gene (90 patients) or detection of the M-bcr rearrangement by Southernblot analysis (12 patients) as described elsewhere. 5, 6 In all, 166 healthy blood donors (82 male and 84 female) served as controls. Briefly, we performed PCR using primers located in introns 9 and 11 (forward 5 0 -CTGAGTGGCTGTGGTAGA GATCC-3 0 , reverse 5 0 -AAAGGAAGCCACTGGAGTTCC-3 0 ) on genomic DNA isolated from peripheral blood leukocytes. Fragments were directly sequenced using an ABI 3730 capillary sequencer.
There were no differences in the genotype frequencies at codon 541 among CML patients and healthy controls (86 Table 1) .
The allele frequencies for the polymorphic variant 541 Leu were 8.3% (n ¼ 17) and 8.1% (n ¼ 27) in patients and controls, respectively. Employing the statistical approach used by Inokuchi et al., 1 there was no significant difference in allele frequencies among patients and controls (P ¼ 1.0, Fisher's exact test). Furthermore, deviations from the Hardy-Weinberg equilibrium were not found (data not shown). Genotype frequencies in our controls were very similar to those observed in another Caucasian population. 7 Notably, Inokuchi et al.
reported frequencies of the polymorphic variant 541
Leu in Japanese CML patients and Japanese controls that were about two times and about ten times lower than in our study, respectively. In addition, we identified two other sequence variants: a silent replacement in exon 10 (c.1638A4G [p.K546K]) and a nucleotide substitution in intron 10 (c.1647 þ 48A4G, Table 1 ).
Because the 541 Leu allele in exon 10 of c-kit was observed with a relatively high frequency of 8.1% in the normal population and had almost the same allele frequency in CML patients, we suggest that this sequence variation is a rather common polymorphism and not a disease-causing or -modifying mutation, and does not seem to be associated with CML, at least not in Caucasians. In contrast, 564
Lys in exon 11 was not found in 166 healthy controls nor in 102 CML patients, suggesting that this variation is not associated with CML in Caucasians.
Our conclusions are further substantiated by three additional observations: (1) All c-kit gain-of-function mutations identified in GIST's and mastocytosis are located in the extracellular domain (corresponding approximately to exon 9), the juxtamembrane domain (corresponding approximately to exon 11), the tyrosine kinase domain I (corresponding approximately to exon 13), or the tyrosine kinase domain II (corresponding approximately to exon 17, also referred to as the activation loop), but not in the transmembrane domain (corresponding approximately to exon 10) in which M541L is situated. 8, 9 This is not the case for N564K, which is located in the juxtamembrane domain.
(2) M541L and N564K do not show the same degree of conservation between species compared to amino-acid positions with proven functional relevance. Alignment was taken from the Ensembl database (www.ensembl.org) using the Clustal W [1.81] multiple sequence alignment method (Table 2) . (3) To further assess the potential functional significance of M541L and N564K, we used the SIFT (Sorting Intolerant From Tolerant amino-acid substitutions) analysis, which uses an evolutionary approach and is based on the assumption that important amino acids tend to be conserved across species. SIFT assigns a substitution probability from 0 to 1 to each possible amino-acid change. Substitutions with probabilities o0.05 are considered as deleterious, whereas those X0.05 are inferred to be tolerated substitutions. 10 SIFT analysis with inclusion of the human c-kit sequence and 33 sequences closely related from various mammalian, amphibian, and fish species revealed M541L and N564K as tolerable amino-acid changes (probabilities of 0.57 and 0.18, respectively). In contrast, all four diseasecausing germline missense mutations so far identified in families with multiple GIST's and confirmed by functional tests were predicted as intolerant (i.e., functionally significant amino-acid substitution) with SIFT probabilities o0.05 (W557R: 0.01, V559A: 0.01, K642E: 0.00, D820Y: 0.00). Taken together, these data do not support a functional importance for the c-kit M541L and N564K variants. These disease-causing germline missense mutations were identified in families with multiple GISTs.
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